Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Dapagliflozin >10 mg provides added benefits in haematocrit, SBP, albuminuria, uric acid

20 Nov 2020

Dapagliflozin therapy with doses higher than 10 mg appears to deliver greater beneficial effects in haematocrit, systolic blood pressure, urinary albumin–creatinine ratio, and uric acid, with no evident increases in the rate of adverse events, a recent study has shown.

A 10-mg dose of dapagliflozin led to an average individual exposure of 638 ng h/mL (95 percent prediction interval [PI], 354–1,061). This translated to 71.2 percent (95 percent PI, 57.9–80.75) of its estimated maximum effect for fasting plasma glucose, 61.1 percent (95 percent PI, 58.0–64.8 percent) for haematocrit, 91.3 percent (95 percent PI, 85.4–94.6 percent) for serum creatinine, and 25.7 percent (95 percent PI, 23.5–28.3) for urinary albumin–creatinine ratio.

“These results raise the question whether future outcome studies assessing the benefits of higher than currently registered dapagliflozin doses are merited,” the investigators said.

This study sought to determine whether the currently registered doses of 5 and 10 mg were optimal for cardiorenal efficacy and safety by describing the relationship between dapagliflozin exposure and nonglycaemic cardiorenal risk markers as well as adverse events.

The investigators collected data from a pooled database of 13 24-week randomized controlled clinical trials of the clinical development programme of dapagliflozin. Population pharmacodynamic and repeated time-to-event models were used to quantify the exposure–response relationship.

“Dapagliflozin is a sodium–glucose co‐transporter 2 inhibitor that has been developed as oral glucose-lowering drug. The original dose-finding studies focused on optimal glycaemic effects. However, dapagliflozin also affects various cardiorenal risk markers and provides cardiorenal protection,” the investigators explained.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.